BIO.News Newsletter

USTR takes action on Mexico’s planned ban on biotech corn, and the FDA grants Priority Review to a breakthrough Alzheimer’s drug. (657 words, 3 minutes, 17 seconds)

The Wall Street Journal Editorial Board weighs in on the recent CMS announcement regarding coverage of breakthrough Alzheimer’s drugs, and a new report on the rise in plastic pollution shows the need for biotech solutions. (643 words, 3 minutes, 12 seconds)

Yesterday’s Senate HELP Committee explained why we need to reform 340B. Plus, we have news about a new coalition (which includes BIO) to fight misinformation and how we can fight avian flu. (723 words, 3 minutes, 36 seconds)

More RSV vaccine news today—plus, how regulatory changes could save horseshoe crabs, reduce methane emissions, and advance biotech innovation. (634 words, 3 minutes, 10 seconds)

Happy March—and Women’s History Month. Today, we have news on Pfizer’s RSV vaccine for older adults and Acceligen’s gene-edited pigs that are resistant to a deadly disease. (650 words, 3 minutes, 15 seconds)

The new season of the I am BIO Podcast is here, with an episode on the dismal pain pipeline and how we can advance needed therapeutics. Plus, we’re showing our stripes on Rare Disease Day in the U.S. and Europe. (690 words, 3 minutes, 27 seconds)

CDC has noticed an increase in “extensively drug-resistant” Shigella infections—the latest evidence of the growing threat of AMR. Plus, the U.S. Chamber released the 11th International IP Index with a warning about the impact of threats to IP on our ability to fight the next pandemic. (516 words, 2 minutes, 34 seconds)

CMS reaffirms its decision on coverage of breakthrough Alzheimer’s drugs—here’s what they said. Plus, we popped into USDA’s Agricultural Outlook Forum yesterday where we heard Secretary Vilsack’s views on SAF and what the administration’s thinking about Mexico. (539 words, 2 minutes, 41 seconds)

With the Farm Bill up for reauthorization this year, a food, agriculture, and biotech industry coalition (including BIO) released policy recommendations. Plus, we look at what’s happening with the biosimilars market in 2023. (579 words, 2 minutes, 53 seconds)

There has been more positive COVID news in recent weeks about the impact of boosters and therapeutics—but we still have work to do on long COVID. (558 words, 2 minutes, 47 seconds)